Kayfanda® Receives Approval for Treatment in the EU
Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This approval represents a crucial step forward in the treatment options available for managing this complex disease.
What is Alagille Syndrome?
Alagille Syndrome (ALGS) is a genetic condition that is passed down through families, marked by developmental issues in the liver, heart, and other essential organs. Children with ALGS often face chronic cholestasis, which can lead to severe complications, such as ongoing liver damage and debilitating itching, known as pruritus. This symptom can significantly affect the daily lives of both the patients and their families.
The Function of Kayfanda®
Kayfanda is designed as a non-systemic ileal bile acid transport (IBAT) inhibitor and is taken once daily. The key ingredient, odevixibat, functions by blocking the ileal bile acid transporter, ultimately lowering serum bile acid levels. This reduction is essential for easing the discomfort associated with cholestasis and the accompanying itching.
Research and Approval Journey
The approval of Kayfanda follows extensive research, particularly through the ASSERT trial. This Phase III clinical trial, the first of its kind focused on ALGS patients, demonstrated that Kayfanda significantly lessens the severity of scratching and enhances overall well-being when compared to a placebo.
Dr. Christelle Huguet on Its Significance
Dr. Christelle Huguet, Executive Vice President at Ipsen, highlighted the importance of this approval. She pointed out the unbearable itching patients often endure and expressed that this new treatment option will greatly improve their quality of life. The launch of Kayfanda is indeed a positive development for patients within the EU.
Broader Implications for Ipsen's Product Line
The introduction of Kayfanda aligns with Ipsen’s dedication to tackling rare diseases, especially in children. Furthermore, Ipsen has expanded its range of treatments for cholestatic liver diseases, now including Iqirvo® (elafibranor) for Primary Biliary Cholangitis. This strategic enhancement positions Ipsen as a leader in innovative solutions for rare liver disorders.
What’s Next for Kayfanda
Kayfanda is also known as Bylvay® in regions outside the EU, where it has already gained approval for treating patients with PFIC. Additionally, ongoing studies, including the BOLD trial, are investigating further uses for odevixibat in Biliary Atresia, with results anticipated around 2026.
Commitment from Ipsen
For families and patients facing the difficulties of ALGS, Ipsen is devoted to offering support and resources. By concentrating on innovative treatments that enhance quality of life, Ipsen strives to be a trusted partner in patient care.
Contact Information
If you're seeking more information regarding Kayfanda and Ipsen’s initiatives, please reach out to:
Craig Marks | + 44 (0)7584 34 91 93 | craig.marks@ipsen.com
Nicolas Bogler | + 33 6 52 19 98 92 | nicolas.bogler@ipsen.com
Frequently Asked Questions
What is Kayfanda® used to treat?
Kayfanda® (odevixibat) is specifically approved for treating cholestatic pruritus in patients diagnosed with Alagille Syndrome.
How does Kayfanda® work?
Kayfanda functions as an ileal bile acid transport inhibitor, which helps lower serum bile acids and reduces itching.
Who qualifies for Kayfanda® treatment?
Kayfanda is approved for use in children aged 6 months and older who have been diagnosed with Alagille Syndrome.
What were the findings from the ASSERT trial?
The ASSERT trial revealed that participants using Kayfanda experienced significant reductions in pruritus symptoms and better sleep quality.
Is Kayfanda® available in markets outside the EU?
Yes, in markets outside the EU, Kayfanda is marketed as Bylvay® and has been approved for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC).
